NDLI: Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer

Content Provider	PubMed Central
Author	Kohli, Manish Young, Charles Yf Tindall, Donald J. Nandy, Debashis Mckenzie, Kyle M. Bevan, Graham H. Donkena, Krishna Vanaja
Copyright Year	2015
Abstract	This study tested the potential of circulating RNA-based signals as predictive biomarkers for docetaxel response in patients with metastatic castration-resistant prostate cancer (CRPC). RNA was analyzed in blood from six CRPC patients by whole-transcriptome sequencing (total RNA-sequencing) before and after docetaxel treatment using the Illumina’s HiSeq platform. Targeted RNA capture and sequencing was performed in an independent cohort of ten patients with CRPC matching the discovery cohort to confirm differential expression of the genes. Response to docetaxel was defined on the basis of prostate-specific antigen levels and imaging criteria. Two-way analysis of variance was used to compare differential gene expression in patients classified as responders versus nonresponders before and after docetaxel treatment. Thirty-four genes with two-fold differentially expressed transcripts in responders versus nonresponders were selected from total RNA-sequencing for further validation. Targeted RNA capture and sequencing showed that 13/34 genes were differentially expressed in responders. Alpha defensin genes DEFA1, DEFA1B, and DEFA3 exhibited significantly higher expression in responder patients compared with nonresponder patients before administration of chemotherapy (fold change >2.5). In addition, post-docetaxel treatment significantly increased transcript levels of these defensin genes in responders (fold change >2.8). Our results reveal that patients with higher defensin RNA transcripts in blood respond well to docetaxel therapy. We suggest that monitoring DEFA1, DEFA1B, and DEFA3 RNA transcripts in blood prior to treatment will be helpful to determine which patients are better candidates to receive docetaxel chemotherapy.
Related Links	http://dx.doi.org/10.2147/OTT.S86637
Ending Page	1922
Page Count	8
Starting Page	1915
File Format	PDF
ISSN	11786930
e-ISSN	11786930
Journal	OncoTargets and therapy
Volume Number	8
Language	English
Publisher	Dove Medical Press
Publisher Date	2015-07-30
Access Restriction	Open
Rights Holder	Dove Medical Press
Subject Keyword	Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Pharmacology (medical) Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer

Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer

Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer

Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer

Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.

Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer

A Long Noncoding RNA, GAS5 Can Be a Biomarker for Docetaxel Response in Castration Resistant Prostate Cancer

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study

Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer

Similar Documents

Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer

Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer

Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer

Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer

Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.

Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer

A Long Noncoding RNA, GAS5 Can Be a Biomarker for Docetaxel Response in Castration Resistant Prostate Cancer

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study

Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer